Medical Condition

copd

Q: How many clinical trials are currently recruiting for copd?

ClinicalMetric currently tracks 29 actively recruiting clinical trials for copd, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 29. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

Q: What trial phases are available for copd?

copd research spans Phase 2 (1 trial), Phase 3 (1 trial), Phase 4 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

Q: How do I find out if I qualify for a copd clinical trial?

Eligibility criteria for copd trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Total Trials

29

Recruiting Now

29

Trial Phases

Phase 2, Phase 3, Phase 4

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, caused primarily by smoking-related airflow obstruction and characterized by progressive dyspnea, chronic bronchitis, and exacerbations that drive hospitalizations and mortality. Despite approval of triple inhaled therapy (LABA/LAMA/ICS), exacerbation rates remain high in eosinophilic phenotypes, driving active trials in targeted biological therapies that have transformed severe asthma management.

Active trials investigate dupilumab for eosinophilic COPD (BOREAS and NOTUS trials showed reduced exacerbations), itepekimab (anti-IL-33), tezepelumab (anti-TSLP), mepolizumab for high-eosinophil COPD, phosphodiesterase-3/4 inhibitors, and novel mucolytic approaches. Disease-modifying trials targeting lung regeneration (all-trans retinoic acid, stem cell therapy) and alpha-1 antitrypsin augmentation for AATD-related COPD are also active.

COPD trials typically require post-bronchodilator FEV1/FVC <0.70 with documented history of exacerbations; blood eosinophil count ≥150 or ≥300 cells/μL is increasingly used to enrich biologic trials.

Frequently Asked Questions — copd Clinical Trials

How many clinical trials are currently recruiting for copd?

ClinicalMetric currently tracks 29 actively recruiting clinical trials for copd, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 29. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for copd?

copd research spans Phase 2 (1 trial), Phase 3 (1 trial), Phase 4 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a copd clinical trial?

Eligibility criteria for copd trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 2

Phase 3

Phase 4

Top Sponsors

University of Colorado, Denver 2 trials

University of Bonn 1 trial

IRCCS San Raffaele Roma 1 trial

Koronis Biomedical Technologies 1 trial

Ting YANG 1 trial

copd

Frequently Asked Questions — copd Clinical Trials

Recruiting Clinical Trials

AYLo - AutoimmunitY and Loss of y

Prevalence of Sarcopenic Obesity in COPD

Inhaler Trainer Efficacy Study

Lung Health of Early COPD: A Multi-center Cohort Study

Right Ventricular Response to Exercise Among Patients With Chronic Obstructive Pulmonary Disease

The Effect of Education and Reminder Messages on the Fatigue Level of Individuals With COPD

Respiratory Syncytial Virus Infection in Exacerbations of Chronic Obstructive Pulmonary Diasease: the RECODE Study

Impact of Remote Vital Signs Monitoring in People Using Long-term Oxygen Therapy

A Study to Evaluate Solrikitug in Participants With COPD (ZION)

Biannual Review of Exhaled Air and Trends in Health Evaluation in COPD

Supporting Evidence-based Responses to Emotional Needs in Emphysema

Effects of Eccentric Exercise Training in Patients With COPD

Reducing Breathlessness With Dronabinol in COPD Patients

Community Exercise Treating Effect on Cardiopulmonary Disease Patients

Integrated Approach in Frail Older People with Atrial Fibrillation

The Clear Conversations Project

Effects of Pulmonary Diseases and Their Treatment on Cardiac Function

Phenotyping Resting and Exertional Right Ventricular Dysfunction Among Patients With Chronic Obstructive Pulmonary Disease

Clinical Study on the Treatment of Stable Bronchiectasis With Bailing Capsules Combined With Guben Kechuan Granules

The Use of Entropy to Assess Sleep Disordered Breathing in Chronic Respiratory Disease

Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD

Assessment the Effectiveness of BTVA in COPD and Ablation in Pulmonary Nodules by Pulmonary MRI

The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)

Effect of Elastic Chest Compression on Functional Exercise Capacity and Respiratory Performance in Patients With COPD

Physiologic Effects of Nasal High Flow on Exercise Tolerance in COPD

Cervical Nags Effect on Accessory Muscles

Ultrasound of the Diaphragm Excursion Ratio as Physiological Biomarker in Acute Exacerbations of Chronic Obstructive Pulmonary Disease

A Translational Study for Prediction of Biomarkers and Identification of Phenotype and Endotype of COPD and Early COPD Outcomes in Chinese Population

Evaluate the Effect of Dietary Supplement Combined Exercise Among Patients With Sarcopenia Comorbid With Lung Disease